New Friends of Cancer Research manuscript in JCO Clinical Cancer Informatics demonstrates the feasibility of aligning disparate real-world (rw) data sources to evaluate rw-response to treatment using clinician-documented response in patients with metastatic non-small cell lung cancer (mNSCLC).
Alignment of methodologies analyzing real-world data (RWD) is critical for supporting evidence generation using these data to inform oncology drug development and regulatory decision-making.
These findings are from the latest pilot project in Friends’ Real-World Evidence Portfolio, which establishes methodologies for using RWD to evaluate safety and efficacy of therapies for #patients.
The study assessed data provided by 7 project partners each providing data from 200 patients, indicating that clinician-documented response data was the most available source data for response assessment across datasets, with variability in the availability of imaging data. Real-world response assessed using clinician-stated response was relatively consistent across #data sources in an aligned patient population.
Read the manuscript here: bit.ly/3LGcdqS
"Evaluation of real-world tumor response derived from electronic health record data sources: A feasibility analysis in mNSCLC #patients treated with chemotherapy.”
This large-scale coordination led by Friends of Cancer Research is developing best practices and alignment for aggregating and analyzing RWD.
Learn more about the Friends Real-World Evidence Portfolio: https://lnkd.in/div5whYW
Thank you to our coauthors: Brittany Avin McKelvey, Elizabeth Garrett-Mayer, PhD, FSCT, Donna Rivera, Amy Alabaster, Hillary Andrews, PhD, Elizabeth G Bond, Thomas D Brown, Amanda Bruno, Lauren Damato, Janet Espirito, Laura Fernandes, Eric Hansen, Paul Kluetz, Xinran Ma, Andrea McCracken, Pallavi Mishra-Kalyani, Yanina (Yana) Natanzon, Danielle Potter, Ph.D., Nicholas Robert, Lawrence Schwartz, Regina Schwind, Connor Sweetnam, Joe Wagner, Mark Stewart, Jeff Allen.
This project is possible through an extensive collaboration with the following partners: American Society of Clinical Oncology (ASCO), ConcertAI, COTA, Flatiron Health, Friends of Cancer Research, Guardian Research Network, IQVIA, Memorial Sloan Kettering Cancer Center, Ontada, Inc., Syapse, Syneos Health, Tempus AI, FDA.